3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Papillomavirus Infections
7
Uterine Cervical Neoplasms
5
Neuroendocrine Tumors
4
Neoplasms
4
Autoimmune Diseases
3
Ovarian Neoplasms
2
Myasthenia Gravis
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Venous Thrombosis
1
Venous Thromboembolism
1
Uterine Cervical Dysplasia
1
Thyroid Diseases
1
Thrombosis
1
Squamous Intraepithelial Lesions
1
Retinal Telangiectasis
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Hairy Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
Data Collection
×
Clear all
NCT03419572
2022-08-15
CASSIOPE
Ipsen
Completed
689 enrolled